JPMorgan Chase & Co. Trims Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

JPMorgan Chase & Co. lowered its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 40.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 1,015,360 shares of the biopharmaceutical company's stock after selling 697,630 shares during the quarter. JPMorgan Chase & Co. owned about 1.78% of Agios Pharmaceuticals worth $33,365,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Vanguard Group Inc. lifted its position in Agios Pharmaceuticals by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock valued at $185,045,000 after purchasing an additional 85,339 shares during the period. State Street Corp boosted its stake in shares of Agios Pharmaceuticals by 10.2% in the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company's stock worth $103,586,000 after buying an additional 216,484 shares during the last quarter. Geode Capital Management LLC grew its holdings in Agios Pharmaceuticals by 0.5% during the third quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company's stock worth $60,326,000 after acquiring an additional 6,101 shares during the period. Frazier Life Sciences Management L.P. raised its position in Agios Pharmaceuticals by 19.7% during the third quarter. Frazier Life Sciences Management L.P. now owns 1,044,154 shares of the biopharmaceutical company's stock valued at $46,392,000 after acquiring an additional 172,180 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its holdings in Agios Pharmaceuticals by 12.3% in the fourth quarter. Fisher Asset Management LLC now owns 960,661 shares of the biopharmaceutical company's stock valued at $31,567,000 after acquiring an additional 105,333 shares during the period.

Remove Ads

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on AGIO shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. StockNews.com downgraded shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, February 14th. Finally, HC Wainwright started coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a "buy" rating and a $58.00 price target for the company. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Agios Pharmaceuticals currently has an average rating of "Hold" and a consensus target price of $56.57.

Agios Pharmaceuticals Stock Up 5.5 %

Shares of NASDAQ AGIO traded up $1.39 during midday trading on Friday, hitting $26.70. The stock had a trading volume of 592,295 shares, compared to its average volume of 711,070. The stock has a 50 day simple moving average of $31.39 and a 200-day simple moving average of $39.24. The company has a market capitalization of $1.53 billion, a PE ratio of 2.35 and a beta of 0.83. Agios Pharmaceuticals, Inc. has a 1 year low of $23.42 and a 1 year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Insider Activity at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the business's stock in a transaction that occurred on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the transaction, the director now directly owns 149,220 shares in the company, valued at $3,864,798. The trade was a 4.78 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.93% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.